log in | register
Username
Password
Remember me
Journals
Services
Search
Advanced search
Summary
August 2007, Vol. 8, No. 12, Pages 1871-1884
(doi:10.1517/14656566.8.12.1871)

Strategies in the treatment of HIV-1-associated adipose redistribution syndromes
María del Mar Gutierrez1 MD, Gracia Mateo2 MD & Pere Domingo MD PhD
1Research fellow, Autonomous University of Barcelona, Infectious Diseases Unit, Hospital de la Sant Creu i Sant Pau, Av. Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain +34 935565609; +34 935565938; ;
2Research Fellow, Autonomous University of Barcelona, Infectious Diseases Unit, Hospital de la Sant Creu i Sant Pau, Av. Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
3Senior Consultant, Autonomous University of Barcelona, Infectious Diseases Unit, Hospital de la Sant Creu i Sant Pau, Av. Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
† Author for correspondence



HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequences may ultimately impact on the adherence to treatment of patients, eventually leading to treatment failure. Despite considerable advances in recent times, the pathogenesis of HALS remains elusive. Factors involved belong to three categories: those intrinsic to the host, some of them modifiable and some not, those associated with antiretroviral therapy, that are sometimes modifiable as well, and finally those related to HIV-1 infection and its consequences, most often not modifiable. The most commonly used strategies for HALS reversion have included host-dependent factors such as lifestyle and dietary modifications and antiretroviral-dependent factors such as switching or avoiding the use of drugs more prone to promote HALS. Lifestyle modifications and switching thymidine analogues have been associated with moderate success. Pharmacological interventions have included the use of insulin-sensitising agents and hormone therapy with disappointing results, whereas treatment with pravastatin or pioglitazone, and uridine supplementation seem to be associated with fat gain in preliminary studies. The only interventions with almost immediate results that may render a patient's appearance similar to his past one have included filling techniques for facial lipoatrophy and ultrasound-assisted liposuction for cervical fat pad hypertrophy. Among the filling options, semipermanent reabsorbable materials and autologous fat transfer have been associated with acceptable outcomes. As of now, the best hope should rely on the use of drugs friendly for fat, on defining the appropriate timing for starting antiretroviral and on continuing the research effort to understand the basic mechanisms underlying HALS pathogenesis. Only through this effort can the best chances for preventing or reverting established HALS be recognised.

Full Text PDF (183.025 KB) PDF Plus (364.046 KB)
 

Prev. Article | Next Article
View/Print PDF (183 KB)
View PDF Plus (364 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

Quick Links
 • Alert me when:
New articles cite this article
 • Download to citation manager
 • Related articles found in:
Expert Opinion series
 • View Most Downloaded Articles
 
 
Quick Search
for 
Authors:
María del Mar Gutierrez
Gracia Mateo
Pere Domingo
Keywords:
abacavir
antiretroviral therapy
fat transfer
filling techniques
HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome
lipoatrophy
lipohypertrophy
liposuction
metformin
NRTIs
pioglitazone
poly-L-lactic acid
polymethylmethacrylate
rosiglitazone
stavudine
switching
tenofovir
uridine


Informa Healthcare, Telephone House, 69-77 Paul Street, London, EC2A 4LQ, UK
Tel: +44 (0)20 7017 5000 · Fax: +44 (0)20 7017 7667
We welcome your Feedback. See our Privacy Statement and Terms and Conditions